Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT03207841 |
Other study ID # |
HHS-2016-ACL-NIDILRR-SI-0158 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
November 1, 2017 |
Est. completion date |
August 29, 2022 |
Study information
Verified date |
March 2023 |
Source |
Ohio State University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Individuals with spinal cord injury (SCI) are living to ages when metabolic disorders are
highly prevalent. The combination of impaired glucose tolerance and insulin resistance can
disrupt lipid metabolism and increase the risk of cardiovascular disease and diabetes, and
contribute to an accelerated aging process in the SCI population. Feasible interventions to
improve metabolic function in the chronic SCI are in great demand. Compared to pharmacologic
therapies, dietary modification is a more cost-effective treatment option for reducing the
risk of metabolic dysfunction that, surprisingly, has not been rigorously investigated in
people with SCI. Therefore, in the present study the investigators will investigate the
efficacy of an 8-week, eucaloric (a meal plan designed specifically to provide the exact
amount of calories needed to maintain a given body weight) LC-HP dietary intervention for
improving metabolic function, body composition, gut bacteria composition and quality of life
in individuals with SCI and impaired glucose tolerance or type 2 diabetes. The investigators
also aim to determine the association between changes in the composition of gut bacteria and
improvements in metabolic function and the association between improvements in metabolic
function and improvements in quality of life.
Description:
Individuals with spinal cord injury (SCI) are living to ages when metabolic disorders are
highly prevalent. Due to the loss of mobility and severe skeletal muscle atrophy in
individuals with SCI, obesity, impaired glucose tolerance, and peripheral insulin resistance
develop after injury . The combination of impaired glucose tolerance and insulin resistance
can disrupt lipid metabolism and increase the risk of cardiovascular disease and diabetes,
and contribute to an accelerated aging process in the SCI population. Because of these
trends, the overall burden of health complications and their economic impact has increased
for individuals with SCI, often leading to a progressive decrease in their long-term quality
of life. Feasible interventions to improve metabolic function (i.e. the way the body
processes proteins, carbohydrates, and fats in foods) in those with chronic SCI are in great
demand. Given that metabolic disorders severely compromise health outcomes and important
domains of quality of life, including participation in daily life and community living and
employment outcomes, targeted strategies to combat these morbidities are of paramount
importance. Compared to pharmacologic therapies, dietary modification is a more
cost-effective treatment option for reducing the risk of metabolic dysfunction that,
surprisingly, has not been rigorously investigated in people with SCI. Much like the general
U.S. population, individuals with SCI consume far more fat and carbohydrate than recommended
levels. High fat, high carbohydrate diets (western diet) have been associated with a higher
prevalence of obesity and metabolic disease as well as negative adaptations in the diversity
of gut bacteria (increased levels of harmful bacteria and reduced levels of beneficial
bacteria) that usually precedes the development of diabetes or insulin resistance. Therefore,
macronutrient (carbohydrate, protein, and fat) modification may be able to prevent or correct
the impaired metabolic state in persons with SCI. Diets composed of relatively high protein
and low carbohydrate have been shown to improve body composition (i.e., reduce body fat while
maintaining lean tissue) and metabolic profiles (i.e., increase in insulin sensitivity and
glucose tolerance) in diabetic, able bodied individuals who are obese or overweight. This
improvement is thought to be due to protein's: (i) effect on the sensation of feeling full
after eating food despite similar or lower energy intake; (ii) contribution to storage of
fat-free mass; and (iii) insulin sensitizing effect.
The investigators' pilot work supports this hypothesis in that we showed that 8 weeks of a
low carbohydrate/high-protein (LC-HP) diet significantly improved whole body insulin
sensitivity (WBIS) and glucose tolerance and decreased the amount of intra-abdominal fat in
six men with SCI and with either untreated type 2 diabetes or impaired glucose tolerance
(pre-diabetes). In addition to significant improvements in metabolic health, our pilot work
also successfully demonstrated the safety and feasibility of our approach. The lack of
adverse effects and the improvement in glucose control and insulin sensitivity in our study
participants with SCI prompted us to propose the current study involving both men and women
in order to determine the effects of the dietary protocol to treat type 2 diabetes or
impaired glucose tolerance in persons with chronic SCI. Thus, the investigators propose an
investigation to determine if 8 weeks of an LC/HP dietary intervention induces the
physiological adaptations necessary to improve metabolic function and body composition and
alter the diversity of gut bacteria in a large cohort of individuals with SCI. The ultimate
outcome of this project will be an effective diet program which can be easily and
economically implemented at home as a non-pharmacological means of achieving blood glucose
control for people with SCI and impaired glucose tolerance or untreated type 2 diabetes.